Skip to main content

Table 2 Clinical characteristics of non-small cell lung cancer patients with brain metastases harboring EGFR mutations

From: Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

CharacteristicsAll patientsPatients with Lung-molGPA 0–2Patients with Lung-molGPA 2.5–4
TKI-naïve group (%)TKI-resistant group (%)pTKI-naïve group (%)TKI-resistant group (%)pTKI-naïve group (%)TKI-resistant group (%)p
All patients207 (100)137 (100) 142 (100)57 (100) 65 (100)80 (100) 
Gender
 Female72 (34.8)53 (38.7) 45 (31.7)21 (36.8) 27 (41.5)32 (40.0) 
 Male135 (65.2)84 (61.3)0.46197 (68.3)36 (63.2)0.48538 (58.5)48 (60.0)0.851
Smoking
 Never97 (46.9)68 (49.6) 60 (42.3)26 (45.6) 37 (56.9)42 (52.5) 
 Current/former110 (53.1)69 (50.4)0.61482 (57.7)31 (54.4)0.66528 (43.1)38 (47.5)0.595
Age
 < 70162 (78.3)112 (81.8) 104 (73.2)43 (75.4) 58 (89.2)69 (86.3) 
 ≥ 7045 (21.7)25 (18.2)0.43138 (26.8)14 (24.6)0.7477 (10.8)11 (13.7)0.588
Histology
 Adenocarcinoma116 (56.0)90 (65.7) 78 (54.9)34 (59.6) 38 (58.5)56 (70.0) 
 Non-adenocarcinoma91 (44.0)47 (34.3)0.07464 (45.1)23 (40.4)0.54427 (41.5)24 (30.0)0.148
KPS
 < 7084 (40.6)57 (41.6) 70 (49.3)36 (63.2) 14 (21.5)21 (26.3) 
 70–100123 (59.4)80 (58.4)0.85072 (50.7)21 (36.8)0.07651 (78.5)59 (73.7)0.510
Number of BM
 1–4124 (59.9)84 (61.3) 80 (56.3)24 (42.1) 44 (67.7)60 (75.0) 
 > 483 (40.1)53 (38.7)0.79362 (43.7)33 (57.9)0.06921 (32.3)20 (25.0)0.331
Extracranial metastases
 Absent81 (39.1)47 (34.3) 23 (16.2)8 (14.0) 58 (89.2)39 (48.8) 
 Present126 (60.9)90 (65.7)0.365119 (83.8)49 (86.0)0.7047 (10.8)41 (51.2)0.352
Primary disease control
 No94 (45.4)63 (46.0) 72 (50.7)32 (56.1) 22 (33.8)31 (38.8) 
 Yes113 (54.6)74 (54.0)0.91770 (49.3)25 (43.9)0.48843 (66.2)49 (61.2)0.542
  1. Abbreviations: NSCLC Non-small-cell lung cancer, BM brain metastasis, Lung-molGPA Lung Cancer Molecular Markers Graded Prognostic Assessment, TKI tyrosine kinase inhibitors, EGFR epidermal growth factor receptor, KPS Karnofsky Performance Status